inflammatory bowel disease

AbbVie and FutureGen Partner on Inflammatory Bowel Disease Treatment

US drugmaker AbbVie and Chinese biopharmaceutical company FutureGen have entered into a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) currently in preclinical testing.

Sanofi Enters into Partnerships with Janssen and Teva

Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, a potential first-in-class product currently in Phase 3.

Sanofi and Lead Pharma Seal Autoimmune R&D Pact